Free James Kimball

The Trials, How Effective Was The Product?

The Trials Conducted At The Universities And With Doctors Using The Product With Their Patients Was A "Huge Success"

Results from universities. Many universities were contacted for their assistance in conducting trials with DEDI's newly revised mineral product.

Temple University in Pennsylvania reported that DEDI's product was very effective in inhibiting fungi. Temple also confirmed that the mineral solution of DEDI's did not appear to attack immune system cells at all, at the strength in which it inhibited fungi.

The University of South Florida conducted tests with DEDI's revised product against deadly strains of bacteria that were resistant to antibiotics called staphylococcus aureus, to include interacoccus which was a deadly form of staph, prevalentonly in hospitals. The results were all positive.

The University of Southern California researcher testing the mineral solutions reported that the preliminary results reflected that the substance reversed the replication of the HIV virus. When this same researcher was contacted after receiving his preliminary findings, he refused to return the calls from DEDI.

It was later learned that he started a company attempting to duplicate the same product as DEDI's. He eventually left the employment of the University of Southern California (USC) after complaints were filed to the university from DEDI.

The researcher's company never could duplicate DEDI's product, however, sold his product based on the trial results of DEDI's product.

Results from doctors. At first only doctors were informed about the testing results conducted at the universities and the NIH. The news spread fast amongst alternative doctors much slower to mainstream medical doctors who had been well educated against using (natural) dietary supplement products as treatments in their patients.

Doctors from around the world started reporting successes they were having using DEDI revised product in their patients.

For more information regarding DEDI's mineral product effectiveness regarding infectious diseases and other viruses click on Infectious Diseases - Is There A Cure? at the top of this page.

DEDI was reluctant to release any information regarding the test results from USC regarding AIDS. This information was withheld from anyone except the scientists and doctors working directly with DEDI in conducting trials with their patients.

Kimball did contact the FDA on a number of occasions regarding preliminary results received from USC about DEDI's product reversing the replication of the AIDS virus. The FDA reflected no interest whatsoever, only adamantly warned Kimball not to reflect such use on the labels of any of his products.

DEDI started receiving calls from full blown AIDS patients that had heard about DEDI's product being effective against viruses, wanting to try the product for their AIDS affliction. Even they were not advised about the USC results.

On one occasion Kimball received a call from an AIDS patient who was in a hospital, expected to live only a few more days, desperately wanting to try DEDI's product. He advised Kimball he was the longest living patient with AIDS in the United States. This was in mid-1995. Kimball decided this would be the first AIDS patient to try DEDI's product. Kimball asked the AIDS patient to have his doctor in Chicago call him regarding the use of DEDI's product.

The patient's doctor called Kimball and advised Kimball he had no objection to his patient receiving and using DEDI's product.

Two 4 oz bottles of the highest potency of DEDI's product were sent to the doctor free of charge to be taken orally, 2 tablespoons a day.

Kimball received a call from the AIDS patient about 10 days later wanting more product. He had been released from the hospital. He explained to Kimball he had taken most all the product DEDI had sent and also had received other experimental medication at the hospital; had gotten better, and left the hospital.

Knowing those facts, there was not any way to know whether DEDI's product did anything to help or not. The patient was complaining that DEDI's product was leaving a horrible taste in his mouth. Kimball knew that at the highest strength of DEDI's product tasted terrible, however at lower strengths DEDI's product had no taste at all.

Kimball advised the AIDS patient that there was nothing he could do about the taste at the highest strength unless he would use lesser strengths which may not be effective at all, regarding HIV. DEDI sent out 2 more bottles free to the patient.

Approximately 10 more days passed before Kimball received another call from the AIDS patient stating he could not tolerate the taste of the product any longer and he was going to stop using it, even though he had remained out of the hospital. Kimball never heard again from this young man.

His case was discussed with closely related doctors to DEDI. As were all the trial reports coming in from doctors around the world. A number of reports were coming in from veterinarian doctors that were injecting the solution into race horses as a last resort to attempt to save their lives from deadly infections they had contracted. The injections were successful in every instance, usually within 24 hours.

It was decided because the product was not tolerable orally at the highest strength, that injections or IVs should be used in patients with AIDS. As DEDI did not have any extra money to conduct FDA required trials and the FDA reflected no interest at all in the product, DEDI needed to secure money and doctors to donate their time to conduct trials privately.

Determining a protocol for administration. Prior to attempting to secure private money and doctors to conduct private trials, a method of administrating DEDI's product needed to be decided.

Many meetings were held and teleconferences transpired prior to the final protocol was decided.

Discussed was the makeup of the product and how DEDI's product being administered directly into the bloodstream could have adverse side effects to the patients.

Because DEDI's product was a specifically engineered silver mineral, wrapped in a specific engineered protein, it was hypothesized that the protein wrapper could cause adverse effects when introduced directly into the bloodstream. This was the main concern.

Because DEDI had removed all other possible contaminates which existed in all other silver solutions over a hundred year period, and while removing all contaminates associated with DEDI's added engineered silver, there was no concern for any side effects from those ingredients. Even the purity of the water content was controlled and monitored.

The big worry was could the human immune system cope with the invasion of an altered protein.

It was decided that the solution DEDI developed would be IV dripped into AIDS patients at 3 different strengths over a 14-day period. The first being at low concentrations, second being at medium concentration, the last being at the highest concentration. It was also concluded it would take 3 IV infusions at the highest strength to potentially kill all the AIDS virus within the body. This due to the fact the HIV virus hides in the lymph system, where the blood supply is very limited.

Securing Money For Private Trials. Kimball wanted to conduct the trials in Africa where people were the hardest hit with the virus. Kimball was to go there himself set up the trials and protocol with local doctors there. It would take from 3-6 months to complete the trials. No one was interested in funding the trials in Africa.

Money and doctors were secured to conduct trials with two full-blown AIDS patients currently in Government medical facilities. The two AIDS patients were terminal expected to live only weeks and volunteered for the trials.

The HIV trials. Around late 1995 the two AIDS patients who volunteered for the trials went through preliminary testing. One AIDS patient that volunteered (name deleted for this accounting) we'll call him Volunteer Patient A, had only full-blown AIDS not any AIDS related diseases and a HIV viral load over the scale of 750,000. While the other AIDS Volunteer Patient B did have AIDS related diseases, to include Hepatitis A, B, and C. His HIV viral load was also over the measurable scale of 750,000.

It was decided that the infusions of DEDI's product must be done outside the U.S. This due to the fact that the FDA had placed doctors, researchers and developers of products in prison, notwithstanding the fact the FDA thumbed its nose at DEDI's product and disliked Kimball intensely.

Arrangements were made and the two volunteers were flown to Mexico to receive their IV infusions.

Because the AIDS volunteers were diagnosed as very near death at the time, everyone was expecting the worst possible side effects from the infusions, to include possible death. Everyone was prepared for the worst, as were the two HIV volunteers.

The infusions were successfully given. The only side effect with Volunteer (VOL) B was, he had flu type symptoms for 2 hours. There were no other side effects noted.

Within a few days both AIDS patients reported they were feeling much better than before the infusions. Approximately ten days after the infusion, the first viral load test was given. We were expecting great results because by this time both HIV volunteers were feeling normal, as if they did not have the virus.

No one knew what either Volunteer's HIV viral load actually was. At the time the method used to measure the HIV viral load was only able to measure a viral load up to 750,000. Both of these volunteers had viral loads over 750,000. The exact amount immeasurable at the time.

When the results came in from the viral load test, everyone was extremely disappointed. The viral load of both volunteers dropped only a very small amount below 750,000.

Although other blood tests taken at the same time revealed their immune system cells had increased, thus their immune systems were stronger.

At this point we had no idea what was going on and we discussed making arrangements for the second and third infusion of the highest strength of DEDI's product in Mexico. However, because the volunteers had reported they both felt better than they had in years and their immune systems were getting stronger we felt we should wait and monitor the two volunteers.

Our conclusion originally was that DEDI's product would have done all it could do within 48 hours in killing the HIV virus. It just didn't do the job despite our own high expectations. Whether or not to complete the next two infusions was in question, as was continuing with any further trials with AIDS.

Four weeks after the first infusion, the two HIV patients were still feeling great. As a long shot we came to the conclusion that because the two volunteers still felt so good that another viral load test should be done along with blood work tests.

We all were in shock when the results of the second viral load test came in regarding the two volunteers. Both their viral loads had dropped dramatically, about 70%. Just as big a surprise was the fact DEDI's product was still working 4 weeks after the infusion.

With this dramatic change in events, it was decided to continue with the trials and schedule the last two infusions in Mexico. We decided we couldn't schedule any further infusions, because we had no idea when DEDI's product would stop working or be removed from the blood system. Again we just had to wait and see.

Because of these amazing results doctors at the Governmental medical facility became aware of the tests and their results.

Kimball made a big mistake and notified personnel at the FDA about the results, hoping for Government support and assistance in formal FDA accepted trials being implemented right away. Kimball received instead of assistance, being offered from FDA personnel, he only received threats.

Over the next few weeks further viral load tests were conducted and blood work done on the two volunteers. The following depicts the testing results and their conclusions.

Once infused at its highest strength DEDI's product appeared to remain within the bloodstream for approximately 60 days.

Volunteer A had a HIV viral load over 750,000 at the start of the first infusion of high strength product. He did not have any AIDS related infections after 60 days his viral load was very close to non-measurable amounts. Two more infusions were recommended. It also appeared after just one infusion that the HIV viral load could be controlled by DEDI's product.

Volunteer B had a HIV viral load of over 750,000 at the start of the first infusion of high strength product. He did have AIDS related serious infections such as Hepatitis A, B, & C. Volunteer B's viral load was reduced to approximately 50,000 before DEDI's product became ineffective after 6 weeks, and the HIV load count began to increase. It was concluded that DEDI's product in Volunteer B with one infusion could not contend as effectively with the AIDS virus, when the patient also had hepatitis A, B, & C. It appears that DEDI's product had depleted its effectiveness in Volunteer B, 2 weeks prior to Volunteer A. This could easily be attributed to the fact that B had Hepatitis A, B, & C and that DEDI's product was not able to effectively kill the AIDS virus and address the patients Hepatitis problems at the same time.

Two more infusions were recommended.

Both volunteers had positive increases within their immune systems.

The end of the trials. Before the two AIDS volunteers could be flown to Mexico to acquire their second IV infusions, Kimball was informed that the two volunteers disappeared from the Government medical facility and could not be found. Also that the medical doctors in the U.S. were questioned about their participation in the trials by Government agents. The trials ended, not be restarted again.

Kimball And His Associates Hold The Records Of
These Trials And The Names Of People Involved

NOTE: Ebola Virus. Around the time the HIV trials were being conducted, an epidemic of the Ebola virus appeared in Africa. DEDI firmly believing their product would effectively cure Ebola; arranged and send to the Red Cross a large quantity of their new product along with the protocols of administration, which were the same as HIV. Approximately two months after DEDI made the arrangements with the Red Cross to deliver DEDI's product to Africa, Kimball received a call from a Red Cross supervisor that the FDA had told the Red Cross not to ship DEDI's product and return the product to DEDI, which the Red Cross did.

Freedom Of Choice In Medicine - Become A Participant

GET INVOLVED

Website Support: This website is financially supported by: Global Health Information and Medical Research Institute, GHI/MRI, a non-profit organization. Information about GHI/MRI located at the top of this page.

Also Supported by:
Citizens Liberty Coalition (CLC)
a subsidiary of GHI/MRI

Get Involved

You Can Stop This

"We" Can Show You "How"!!

Participate In CLC

You can change things "FAST"

!! We'll show you how!!